TY  - JOUR
AU  - Odabashian, Roupen
AU  - Bastin, Donald
AU  - Jones, Georden
AU  - Manzoor, Maria
AU  - Tangestaniapour, Sina
AU  - Assad, Malke
AU  - Lakhani, Sunita
AU  - Odabashian, Maritsa
AU  - McGee, Sharon
PY  - 2024
DA  - 2024/1/12
TI  - Assessment of ChatGPT-3.5's Knowledge in Oncology: Comparative Study with ASCO-SEP Benchmarks
JO  - JMIR AI
SP  - e50442
VL  - 3
KW  - artificial intelligence
KW  - ChatGPT-3.5
KW  - language model
KW  - medical oncology
AB  - Background: ChatGPT (Open AI) is a state-of-the-art large language model that uses artificial intelligence (AI) to address questions across diverse topics. The American Society of Clinical Oncology Self-Evaluation Program (ASCO-SEP) created a comprehensive educational program to help physicians keep up to date with the many rapid advances in the field. The question bank consists of multiple choice questions addressing the many facets of cancer care, including diagnosis, treatment, and supportive care. As ChatGPT applications rapidly expand, it becomes vital to ascertain if the knowledge of ChatGPT-3.5 matches the established standards that oncologists are recommended to follow. Objective: This study aims to evaluate whether ChatGPT-3.5’s knowledge aligns with the established benchmarks that oncologists are expected to adhere to. This will furnish us with a deeper understanding of the potential applications of this tool as a support for clinical decision-making. Methods: We conducted a systematic assessment of the performance of ChatGPT-3.5 on the ASCO-SEP, the leading educational and assessment tool for medical oncologists in training and practice. Over 1000 multiple choice questions covering the spectrum of cancer care were extracted. Questions were categorized by cancer type or discipline, with subcategorization as treatment, diagnosis, or other. Answers were scored as correct if ChatGPT-3.5 selected the answer as defined by ASCO-SEP. Results: Overall, ChatGPT-3.5 achieved a score of 56.1% (583/1040) for the correct answers provided. The program demonstrated varying levels of accuracy across cancer types or disciplines. The highest accuracy was observed in questions related to developmental therapeutics (8/10; 80% correct), while the lowest accuracy was observed in questions related to gastrointestinal cancer (102/209; 48.8% correct). There was no significant difference in the program’s performance across the predefined subcategories of diagnosis, treatment, and other (P=.16, which is greater than .05). Conclusions: This study evaluated ChatGPT-3.5’s oncology knowledge using the ASCO-SEP, aiming to address uncertainties regarding AI tools like ChatGPT in clinical decision-making. Our findings suggest that while ChatGPT-3.5 offers a hopeful outlook for AI in oncology, its present performance in ASCO-SEP tests necessitates further refinement to reach the requisite competency levels. Future assessments could explore ChatGPT’s clinical decision support capabilities with real-world clinical scenarios, its ease of integration into medical workflows, and its potential to foster interdisciplinary collaboration and patient engagement in health care settings. 
SN  - 2817-1705
UR  - https://ai.jmir.org/2024/1/e50442
UR  - https://doi.org/10.2196/50442
DO  - 10.2196/50442
ID  - info:doi/10.2196/50442
ER  -